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Abstract 
Background: Postprandial hyperglycemia plays an important role in the pathogenesis of coronary artery disease 
and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of postprandial 
hyperglycemia. However, the impact of 1,5-AG level on cardiovascular events has not been fully investigated.
Methods: We enrolled 240 consecutive patients who had undergone first-time elective percutaneous coronary 
intervention (PCI) with follow-up angiography within 1 year. We excluded patients with a history of acute coronary 
syndrome, advanced chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m2), or uncon-
trolled diabetes mellitus (HbA1c ≥7.0%). Fasting blood glucose (FBS), HbA1c, and 1,5-AG levels were measured prior 
to PCI and at the time of follow-up angiography. Clinical events, including target lesion revascularization, target vessel 
revascularization, and revascularization of new lesions, were evaluated.
Results: Subjects were divided into two groups according to clinical outcomes: the Event (+) group (n = 40) and 
the Event (−) group (n = 200). No significant differences were observed, except for the number of diseased vessels 
and the prevalence of statin use, in baseline clinical characteristics between the two groups. Serum levels of 1,5-AG at 
follow-up were significantly lower in the Event (+) group than in the Event (−) group (P = 0.02). A significant reduc-
tion in 1,5-AG level from baseline to follow-up was observed in the Event (+) group compared with the Event (−) 
group (P = 0.04). The association between 1,5-AG levels at follow-up and clinical events remained significant after 
adjustment for independent variables, including FBS and HbA1c levels (P = 0.04).
Conclusions: Low and exacerbated levels of 1,5-AG were associated with cardiovascular events in the present study, 
indicating that postprandial hyperglycemia is an important risk factor for adverse clinical events even in patients with 
HbA1c < 7.0%, following first-time elective PCI.
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Background
Postprandial hyperglycemia is considered to be a risk 
factor for atherosclerotic diseases such as coronary 
artery disease (CAD) [1–5]. Serum 1,5-anhydroglucitol 
(1,5-AG) levels better reflect short-term glucose control 
and postprandial hyperglycemia than do hemoglobin 
A1c (HbA1c) levels [6, 7]. Therefore, the measurement 
of 1,5-AG levels may have utility as a clinical marker of 
glycemic control in patients with CAD. Indeed, previous 
studies have reported that 1,5-AG levels are associated 
with vascular endothelial dysfunction [8], carotid athero-
sclerosis [9], and CAD [10, 11]. In addition, 1,5-AG levels 
predicted cardiovascular events in two previous popu-
lation-based cohorts and a clinical study with relatively 
small-sample sizes [12–14].
However, the association between 1,5-AG levels and 
cardiovascular events in patients with CAD is unclear. 
Moreover, the American Diabetes Association and 
the European Association for the Study of Diabetes 
have recommended that a reasonable HbA1c goal for 
adult patients with diabetes mellitus (DM) is  <7.0% 
(53  mmol/mol) [15, 16]. To date, appropriate glycemic 
control markers for preventing cardiovascular events in 
patients with CAD and HbA1c level <7.0% have yet to be 
reported. Therefore, we examined whether serum 1,5-
AG levels can predict adverse cardiovascular events in 
patients with HbA1c level <7.0% after first-time elective 
percutaneous coronary intervention (PCI).
Methods
Study subjects
The present study was a retrospective observational study. 
The study was approved by the institutional review board 
at the Juntendo University and performed in accordance 
with the principals of the Declaration of Helsinki. Written 
informed consent was obtained from all patients. First, we 
recruited 538 consecutive subjects after first-time elective 
PCI with drug-eluting stents (DES) between April 2011 
and January 2015. Patients meeting the following crite-
ria were excluded: no follow-up angiography, a history of 
acute coronary syndrome (ACS), estimated glomerular 
filtration rate  <30  mL/min/1.73  m2 calculated using the 
modification of diet in renal disease equation modified 
with a Japanese coefficient using baseline serum creati-
nine [17], HbA1c  ≥7.0%, under treatment with sodium 
glucose co-transporter 2 inhibitors, a history of gastrec-
tomy, or previous bare-metal stent implantation.
Data collection
Clinical characteristics, including age, gender, body-mass 
index (BMI), smoking habit, a history of hypertension, 
history of DM, family history of CAD, ejection fraction, 
blood pressure, and concomitant use of medication, were 
collected at the time of PCI. Biochemical variables from 
blood samples were evaluated after an overnight fast. 
Hypertension was defined as a systolic blood pressure 
≥140  mmHg, a diastolic blood pressure ≥90  mmHg or 
treatment with antihypertensive medication. DM was 
defined as a fasting blood glucose ≥126  mg/dL, serum 
HbA1c level ≥6.5%, or treatment with an oral antihy-
perglycemic drug or insulin injections. Current smokers 
were defined having smoked at the time of PCI or had 
quit within 1 year prior to the study period. We defined 
ACS as unstable angina pectoris (UAP), non-ST seg-
ment elevation myocardial infarction (NSTEMI), or ST 
segment elevation myocardial infarction (STEMI). UAP 
was defined as having angina at rest or in an accelerating 
pattern with negative cardiac biomarkers and transient 
ischemic ST segment shift. Myocardial infarction was 
defined as an increase in serum cardiac enzymes (tro-
ponin, CK ≥ twofold increase).
Blood samples
We obtained blood samples immediately prior to coro-
nary stenting and at the time of follow-up angiography 
within 1  year. Samples were stored at −80  °C for later 
measurement of 1,5-AG levels. Serum levels of 1,5-AG 
were measured by a colorimetric method (Nippon Kay-
aku, Tokyo, Japan) using a Lana 1,5-AG auto liquid auto-
matic analyzer (JCA-BM 8060, JEOL Ltd., Tokyo, Japan). 
HbA1c levels were measured by high-performance liquid 
chromatography (TOHSOH, Tokyo, Japan). Serum levels 
of total cholesterol, triglycerides and high-density lipo-
protein (HDL) cholesterol were measured by standard 
enzymatic methods (Kainos, Tokyo, Japan), and low-den-
sity lipoprotein (LDL) cholesterol values were measured 
by the direct method. High-sensitivity C-reactive protein 
(CRP) levels were measured by latex photometric immu-
noassay (CRP-Latex “Seiken,” Denka Seiken, Inc.) with an 
autoanalyzer (Hitachi H7350). Blood glucose levels were 
measured using an enzymatic method. These assays have 
inter- and intra-assay coefficients of variation of 0.5 and 
0.4% for 1,5-AG, 1.1 and 0.9% for HbA1c, 1.9 and 0.5% 
for blood glucose, 1.4 and 1.5% for total cholesterol, 1.3 
and 0.6% for triglycerides, 2.1 and 1.1% for HDL-choles-
terol, and 1.9 and 0.6% for LDL-cholesterol, respectively.
Angiographical analysis
Coronary angiography was performed on all patients at 
baseline. The extent of stenosis was measured by the num-
ber of stenotic vessels recorded as 1-, 2-, 3-vessel disease 
or stenosis of the left main artery. Narrowing of the pre-
stenotic diameter of the blood vessels 75% was considered 
significant stenosis. Quantitative coronary angiography 
(QCA) assessments were performed in all subjects. All 
QCA analyses were performed by a technician without any 
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knowledge of the study results as previously described [18, 
19]. Absolute values for the mean reference diameter and 
minimal luminal diameter were determined. All PCI pro-
cedural decisions, including device selection and adjunctive 
pharmacotherapy, were made at the discretion of the indi-
vidual PCI operator. Intravenous unfractionated heparin 
and intracoronary nitroglycerin were administered prior 
to PCI. After DES implantation, angiographic optimization 
was performed using high-pressure dilatation to achieve an 
acceptable angiographic result. Intravascular ultrasound 
was performed at the operator’s discretion. Procedural 
success was defined as a residual stenosis  <20% without 
major complications. Dual antiplatelet therapy (100  mg 
aspirin with 200 mg ticlopidine or 75 mg clopidogrel) was 
prescribed to all patients treated with DES until follow-up 
coronary angiography at the earliest. Target lesion revascu-
larization (TLR) was defined as repeat PCI within the index 
procedure stent or 5 mm edge. Target vessel revasculariza-
tion (TVR) was defined as repeat PCI in the target vessel. A 
new lesion was defined as de novo lesions requiring revas-
cularization except for TLR and TVR.
Statistical analysis
All results are expressed as percentages for categorical 
variables and as the mean ± standard deviation for con-
tinuous variables. Baseline data were compared using 
Student’s t test or the Mann–Whitney U test for con-
tinuous variables. Categorical variables were compared 
using the Chi square test. Multivariate logistic regression 
analysis was performed to identify independent factors 
for adverse clinical events, including age, gender, BMI, 
and all variables with a P value <0.2 on univariate logistic 
regression analysis. P values <0.05 were considered statis-
tically significant. All data were analyzed using JMP ver-
sion 11.0 for Windows (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
During the study period, 538 patients underwent first-
time elective PCI in our institution. We excluded 182 
patients without follow-up angiography, 18 patients 
with advanced chronic kidney disease, 49 patients with 
HbA1c ≥7.0% at baseline, 34 patients who underwent PCI 
with bare-metal stents, 8 patients with ACS, 5 patients 
with a history of gastrectomy, and 2 patients with data 
loss. As a result, a total of 240 consecutive patients who 
had undergone first-time elective PCI were enrolled into 
the present study (Fig. 1). The mean follow-up period was 
252 days (range 105–360 days). During the follow-up, 13 
patients received TLR, 4 patients received TVR, and 23 
patients received revascularization for de novo lesions.
Subjects were divided into two groups according to 
clinical outcomes: the Event (+) group (n = 40) and the 
Event (−) group (n = 200). Clinical characteristics, labo-
ratory findings, and concomitant use of medications are 
shown Tables  1, 2 and 3, respectively. At baseline, the 
number of diseased vessels significantly differed between 
the two groups. The prevalence of statin use was sig-
nificantly higher in the Event (−) group at baseline. No 
significant differences in clinical characteristics were 
observed between the two groups at follow-up.
Change in glycemic markers
Regarding baseline glycemic markers, no significant dif-
ferences in FBS, HbA1c, or 1,5-AG levels were observed 
between the two groups. However, at follow-up, serum 
levels of 1,5-AG (14.5  ±  6.6 vs. 17.3  ±  7.0  μg/mL, 
240 patients were included in
the final analysis 
40 Patients with event group
Event (+)
200 Patients without event group 
Event (−)
538 Patients who underwent first-time elective PCI
between  April 2011 and January 2015
298 Patients were excluded
182 had  no follow-up angiography 
18 had advanced chronic kidney disease
49 had uncontrolled diabetes mellitus
34 underwent PCI with bare-metal stents
8 had a history of acute coronary syndrome
5 underwent gastrectomy
2 had  data loss
Fig. 1 Flow chart of study population. PCI percutaneous coronary 
intervention
Table 1 Patient characteristics at baseline
Data are presented as mean ± SD or number (%)






Age (years) 68 ± 9 69 ± 10 0.54
Male, n (%) 32 (80) 164 (82) 0.77
BMI (kg/m2) 24.6 ± 3.1 24.4 ± 3.2 0.74
Hypertension, n (%) 30 (75) 148 (74) 0.89
Diabetes mellitus, n (%) 13 (33) 57 (29) 0.61
Current smoker, n (%) 10 (25) 38 (19) 0.40
Family history of premature 
CAD, n (%)
6 (15) 52 (26) 0.11
EF (%) 62 ± 12 66 ± 8 0.10
No. of diseased vessels 0.03
 One, n (%) 9 (22) 93 (46)
 Two, n (%) 18 (45) 73 (37)
 Three, n (%) 12 (30) 32 (16)
 Stenosis of left main 
artery, n (%)
1 (3) 2 (1)
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P  =  0.02), but not FBS (100  ±  19 vs. 97  ±  18  mg/dl, 
P = 0.31) or HbA1c (6.0 ± 0.7 vs 5.9 ± 0.5%, P = 0.84), 
were significantly different between the Event (+) group 
and the Event (−) group (Table  4). Interestingly, a sig-
nificant reduction in 1,5-AG levels from baseline was 
observed in the Event (+) group compared to the Event 
(−) group (−2.0 ± 4.0 vs. −0.5 ± 4.2 μg/mL, P = 0.04) at 
follow-up (Fig. 2).
The association between 1,5-AG level and clinical 
adverse events remained significant after adjustment for 
other variables, including age, male gender, BMI, fam-
ily history of premature CAD, HDL-cholesterol, statin 
therapy, and multiple diseased vessels (OR 0.94; 95% CI 
0.89–0.99; P = 0.04; Table 5).
Discussion
The results of the present study indicate low and exac-
erbated levels of 1,5-AG are associated with clinical 
events in patients with first-time elective PCI. Previous 
reports demonstrating the association between 1,5-AG 
and cardiovascular complications have included in pop-
ulation-based cohort studies [12, 13] and patients with 
CAD, including those with relatively high HbA1c levels 
[14]. This is the first study, to report serum 1,5-AG lev-
els as significantly associated with clinical events in CAD 
patients with HbA1c levels <7.0%.
DM and impaired glucose tolerance play an impor-
tant role in the pathogenesis of cardiovascular events, 
including the incidence of restenosis following PCI [20]. 
Table 2 Clinical and laboratory findings at baseline and follow-up
Data are presented as mean ± SD
HDL high-density lipoprotein, LDL low-density lipoprotein, CRP C-reactive protein, BNP brain natriuretic peptide
Baseline Follow-up









Systolic blood pressure (mmHg) 148 ± 26 143 ± 21 0.20 147 ± 25 142 ± 23 0.22
Diastolic blood pressure (mmHg) 82 ± 14 79 ± 13 0.15 82 ± 13 79 ± 14 0.23
HDL cholesterol (mg/dl) 45 ± 10 44 ± 12 0.75 49 ± 14 46 ± 13 0.19
LDL cholesterol (mg/dl) 96 ± 30 90 ± 23 0.17 84 ± 25 84 ± 20 0.98
Triglyceride (mg/dl) 137 ± 55 127 ± 61 0.34 124 ± 86 119 ± 57 0.66
Creatinine (mg/dl) 0.79 ± 0.17 0.79 ± 0.20 0.82 0.83 ± 0.21 0.80 ± 0.21 0.36
Hs-CRP (mg/L), median (25th–75th) 0.08 (0.04–0.15) 0.08 (0.03–0.22) 0.75 0.05 (0.03–0.13) 0.07 (0.03–0.17) 0.65
BNP (pg/ml), median (25th–75th) 34 (23–62) 30 (14–68) 0.28 28 (14–77) 30 (15–56) 0.90
Table 3 Medical therapy at baseline and follow-up
Data are presented as number (%)











Aspirin, n (%) 39 (98) 199 (99) 0.28 40 (100) 199 (99) 0.55
Calcium-channel blocker, n (%) 19 (48) 103 (52) 0.64 20 (50) 110 (55) 0.56
Beta-blocker, n (%) 18 (45) 104 (52) 0.42 15 (38) 104 (52) 0.09
ACE inhibitor or ARB, n (%) 19 (48) 104 (52) 0.60 21 (53) 109 (55) 0.82
Statin, n (%) 20 (50) 137 (69) 0.03 34 (85) 175 (88) 0.67
Sulfonylurea, n (%) 4 (10) 13 (7) 0.45 4 (10) 13 (7) 0.45
DPP-4 inhibitor, n (%) 3 (8) 24 (12) 0.39 4 (10) 24 (12) 0.71
Metformin, n (%) 3 (8) 12 (6) 0.73 3 (8) 12 (6) 0.73
Pioglitazone, n (%) 1 (3) 5 (3) 1.00 1 (3) 5 (3) 1.00
Glinide, n (%) 2 (5) 7 (4) 0.66 2 (5) 6 (3) 0.54
Alpha-glucosidase inhibitor, n (%) 5 (13) 11 (6) 0.14 4 (10) 9 (5) 0.20
Insulin, n (%) 4 (10) 7 (4) 0.11 4 (10) 7 (4) 0.11
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Nonetheless, target values of glycemic control in patients 
with DM have not been fully determined. Previous clini-
cal trials have demonstrated little benefit of intensive gly-
cemic therapy to lower HbA1c levels in patients with DM 
for the prevention of cardiovascular events [21–23]. In 
addition, the utility of other glycemic markers as clinical 
predictors of adverse cardiovascular events in patients 
with CAD remains unknown. Recently, postprandial 
hyperglycemia has been posited as a risk factor for CAD 
[1–5, 24]. We previously reported that patients with mul-
tivessel CAD had slightly but significantly higher blood 
glucose levels at 1  h after a 75-g oral glucose tolerance 
test compared to subjects without CAD, even in subjects 
with normal glucose tolerance [25]. Therefore, there is 
a clinical need for a glycemic marker that reflects post-
prandial hyperglycemia in order to identify patients at 
high risk of cardiovascular events despite the absence of 
DM.
Serum 1,5-AG levels better reflect short-term glucose 
control and postprandial hyperglycemia than hemo-
globin A1c (HbA1c) levels [6, 7]. Previous studies have 
reported that 1,5-AG levels are associated with vascular 
endothelial dysfunction [8] and cardiovascular diseases 
[9–11]. In addition, 1,5-AG levels were found to predict 
cardiovascular events in two population-based cohorts 
and a clinical study with a small-sample size [12–14]. 
Watanabe et al. reported that the adjusted hazard ratios 
(HRs) of all cardiovascular diseases in men increased 
linearly (P = 0.004) and the adjusted HR was 2.22 (95% 
CI 1.24–3.98) in the lowest 1,5-AG category in a popu-
lation-based cohort study comprising 2095 Japanese 
individuals without a history of CAD or stroke [12]. In 
the Atherosclerosis Risk in Communities study involv-
ing 11,106 participants without cardiovascular disease at 
baseline, Selvin et al. recently showed that subjects with 
DM and 1,5-AG  <6.0  mg/mL had an increased risk of 
Table 4 Glycemic markers at baseline and follow-up
Data are presented as mean ± SD
FBS fasting blood glucose, HbA1c hemoglobin A1C, 1,5-AG 1,5-anhydroglucitol
Baseline Follow-up
Event (+)  
(n = 40)
Event (−)  
(n = 200)
P value Event (+)  
(n = 40)
Event (−)  
(n = 200)
P value
FBS (mg/dl) 100 ± 15 97 ± 19 0.41 100 ± 19 97 ± 18 0.31
HbA1c (%) 5.9 ± 0.5 5.9 ± 0.5 0.77 6.0 ± 0.7 5.9 ± 0.5 0.84
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Fig. 2 Serum 1,5-AG levels and change in 1,5-AG levels. a Serum levels of 1,5-AG at baseline and follow-up in the two groups. Data are presented as 
a box plot with the 25th–75th percentiles containing the median line and lines depicting the 10th–90th percentiles. 1,5-AG, 1,5-anhydroglucitol.  
b Changes in 1,5-AG levels between the two groups. Data are presented as mean ± SD
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CAD (HR 3.85, 95% CI 3.11–4.78), stroke (HR 3.48, 95% 
CI 2.66–4.55), heart failure (HR 3.50, 95% CI 2.93–4.17), 
and death (HR 2.44, 95% CI 2.11–2.83) compared with 
subjects with 1,5-AG ≥6  mg/mL and no history of DM 
[13]. In 141 patients after PCI, Fujiwara et al. [14] dem-
onstrated that 1,5-AG levels were significantly lower in 
patients with any coronary revascularization (P = 0.005) 
and target lesion revascularization. Moreover, appropri-
ate glycemic control markers for preventing cardiovascu-
lar events in patients with CAD and HbA1c levels <7.0% 
have yet to be reported. In the present study, low and 
exacerbated levels of 1,5-AG were important risk fac-
tors for adverse clinical events in patients with HbA1c 
levels  <7.0% after first-time elective PCI. Therefore, the 
measurement of 1,5-AG level may be important, not only 
for the assessment of postprandial hyperglycemia, but 
identifying patients at high risk of adverse clinical events, 
even in CAD patients with HbA1c levels <7.0%.
Several recent studies have reported the associations 
between 1,5-AG levels and cardiovascular disorders 
[26–29]. A low 1,5-AG levels has been associated with 
elevated cardiac troponin T and prospectively associ-
ated with the 6-year incident elevation in troponin T 
levels in patients with DM [26]. This may be linked to 
a possible harmful effect of hyperglycemic peaks on 
the myocardium or on the microvascular supply to the 
myocardium [26]. However, whether the associations 
between a low 1,5-AG levels and myocardial damage are 
independent of average glucose level remains unclear 
[26]. A recent study demonstrated that the 1,5-AG level 
is negatively associated with hypoglycemia in patients 
with well-controlled DM receiving insulin therapy [27]. 
This finding suggests that low 1,5-AG levels are associ-
ated with severe glycemic variability due to postprandial 
hyperglycemia and enhanced hypoglycemia, which affect 
the 1,5-AG level in opposing directions, in patients with 
well-controlled DM with relatively low HbA1c levels. 
In contrast, glycated albumin levels have been found to 
be more closely correlated with CAD than 1,5-AG and 
HbA1c levels in 272 Chinese subjects [28]. Compared 
with 1,5-AG levels, glycated albumin and HbA1c levels 
have been found to provide superior discrimination for 
carotid wall thickness in community-dwelling Japanese 
subjects with glucose intolerance [29]. Both these stud-
ies had a cross-sectional design. In the former study 
assessed by the coronary stenosis index, the clinical char-
acteristics, including age, gender, lipid profile, prevalence 
of DM, and concomitant use of medications for dys-
lipidemia and DM, were significantly different. There-
fore, several confounding factors may have affected the 
Table 5 Results of univariate and multivariate analyses at follow-up
Age, male gender, BMI, and variables with a P value <0.20 on Univariate analysis were analyzed by multivariate logistic regression
OR odds ratio, CI confidence interval, BMI body-mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, FBS fasting blood glucose, HbA1c hemoglobin 
A1C, 1,5-AG 1,5-anhydroglucitol
Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Age (years) 0.99 0.95–1.02 0.52 0.96 0.92–1.00 0.05
Male—yes 0.88 0.39–2.19 0.77 1.06 0.41–2.95 0.91
BMI (kg/m2) 0.98 0.87–1.09 0.73 0.98 0.86–1.11 0.72
Current smoker—yes 1.42 0.61–3.08 0.40
Family history of premature CAD—yes 0.50 0.18–1.17 0.11 0.37 0.12–0.96 0.04
Systolic blood pressure (mmHg) 1.01 0.99–1.03 0.21
Diastolic blood pressure (mmHg) 1.02 0.99–1.04 0.23
HDL cholesterol (mg/dL) 1.02 0.99–1.04 0.19 1.02 0.99–1.05 0.12
LDL cholesterol (mg/dL) 1.00 0.98–1.02 0.98
Triglyceride (mg/dL) 1.00 0.99–1.01 0.66
Creatinine (mg/dL) 2.08 0.41–9.63 0.36
Hs-CRP (mg/L) 0.79 0.28–1.31 0.46
FBS (mg/dL) 1.01 0.99–1.03 0.33
HbA1c (%) 0.94 0.49–1.70 0.84
1,5-AG (μg/mL) 0.94 0.89–0.99 0.02 0.94 0.89–0.99 0.04
Hypoglycemic therapy—yes 1.47 0.66–3.12 0.34
Anti-hypertensive therapy—yes 0.96 0.39–2.72 0.94
Statin therapy—yes 0.46 0.23–0.92 0.03 0.44 0.21–0.93 0.03
Multiple diseased vessels—yes 2.99 1.41–6.98 0.004 3.41 1.54–8.23 0.002
Page 7 of 8Takahashi et al. Cardiovasc Diabetol  (2016) 15:145 
results. Further prospective studies in a larger population 
are required to assess the relationship between the 1,5-
AG level and cardiovascular diseases.
The present study has several limitations. First, this 
was a single-center study and the study sample size was 
small. Second, subjects were exclusively patients who had 
undergone first-time elective PCI and follow-up angi-
ography. Third, we were unable to determine all clinical 
characteristics with an effect on 1,5-AG levels (e.g., renal 
glycosuria). Forth, there was individual variation in the 
follow-up angiography period. Fifth, we did not perform 
a 75gOGTT in all non-diagnosed DM patients in the pre-
sent study. This may have led to underestimation of the 
number of patients with DM. We think that the measure-
ment of serum levels of 1,5-AG may be useful for evalu-
ating not only postprandial hyperglycemia but also DM 
in the clinical setting without a 75gOGTT, even in those 
with HbA1c <7.0%. Finally, the study follow-up duration 
was not long term. Accordingly, it was relatively difficult 
to evaluate major adverse cardiovascular events, includ-
ing all-cause mortality, nonfatal myocardial infarction, 
and nonfatal stroke. Therefore, the results of the present 
study require further confirmation in a larger population 
cohort over a long-term period.
Conclusions
The present study demonstrated that low and exacer-
bated levels of 1,5-AG were associated with cardiovas-
cular events, indicating postprandial hyperglycemia is an 
important risk factor for adverse clinical events even in 
patients with HbA1c levels <7.0%, after first-time elective 
PCI.
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